![ORCID Icon]({"type":"image","src":"/templates/jsp/_style2/_tandf/images/orcid.svg"} "ORCID Icon"){kind=small}
http://orcid.org/0000-0002-3381-2641
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
![Publish Open Access Finland]({"type":"image" , "src" : "/sda/110396/JournalAd-OA-Agreements.gif"})
![Annals of medicine, now fully Open Access!]({"type":"image" , "src" : "/sda/110652/IANN-Endocrinology.gif"})
Abstract
Background: Previous reports demonstrated the role of TP53 gene polymorphisms with CRC risk among several ethnic populations. The purpose of this study is to assess the association of the TP53 Arg72Pro and Pro47Ser variants with CRC risk among Egyptian patients.
Subjects and Methods: This work was conducted on 120 unrelated CRC Egyptian patients who were compared to 140 healthy controls. DNA was genotyped for these variants using the PCR-RFLP technique.
Results: CRC patients observed a significant association of the rare genotype of TP53 Arg72Pro polymorphism compared with healthy controls. On the contrast, all genetic models showed no statistical association of TP53 Pro47Ser polymorphism among CRC patients compared with healthy controls. On the contrast, CRC patients of the TP53 gene polymorphisms indicated no significant difference regarding their clinical and laboratory markers.
Conclusions: Our findings indicate a strong association with TP53 Arg72Pro variant within increased risk of CRC among Egyptian patients.
Acknowledgements
Authors are grateful to the staff members of Damietta Cancer Institute, Damietta, Egypt for their help in selecting cases under the study.
Disclosure statement
The authors declare that they have no conflict of interest related to this work.